Drug Trial Radar · NCT04428788
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
131
Actual
Start
Jun 22, 2020
Primary completion
Oct 28, 2025
Study completion Oct 28, 2025
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jun 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Conditions
- Prostatic Neoplasms
Interventions
CC-94676Drug
Specified dose on specified days
CC1083611Drug
Specified dose on specified days
CC1083610Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs) evaluated using the NCI CTCAE v5.0 criteriaTime frame: From the time of consent at screening until 28 days after thesubject discontinues study treatment.
- Dose-limiting toxicity (DLT)Time frame: Up to 35 days
- Non-tolerated dose (NTD)Time frame: Up to 35 days
- Maximum tolerated dose (MTD)Time frame: Up to 35 days
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Local Institution - 116
Stanford, California
Local Institution - 122
Washington D.C., District of Columbia
Local Institution - 103
Sarasota, Florida
Local Institution - 121
Thomasville, Georgia
Local Institution - 108
Baltimore, Maryland
Local Institution - 104
Boston, Massachusetts
Local Institution - 117
Ann Arbor, Michigan
Local Institution - 102
Grand Rapids, Michigan
Local Institution - 112
New York, New York
Local Institution - 109
New York, New York
Local Institution - 105
New York, New York
Local Institution - 106
Durham, North Carolina
Local Institution - 120
Allentown, Pennsylvania
Local Institution - 113
Philadelphia, Pennsylvania
Local Institution - 107
Dallas, Texas
Local Institution - 119
Houston, Texas
Local Institution - 101
San Antonio, Texas
Local Institution - 115
Seattle, Washington
Local Institution - 111
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.